Fertility preservation refers to every particular method in reproductive medicine performed in order to save reproductive function in special populations who are threatened of losing their reproductive capability. This approach is becoming very popular within the last five years due to the increasing number of cancer survivors among young females of reproductive age.

Both chemotherapy and radiotherapy are toxic to the ovaries. Therefore, they may reduce the number of follicles, as determined by the patients' age, dosages, and type of chemotherapeutic agents utilized. Women receiving alkylating agents have an increased risk for loss of follicles by 3.8 times, while platinum based chemotherapeutic agents will have an increased risk of 1.8-fold. Older women need only lower dosages of chemotherapy in order to cause follicle loss, leading to infertility or ovarian insufficiency.

Before offering fertility preservation, doctors and patients should first determine the possibility of delaying cancer treatment. If possible, oocyte or embryo freezing is a preferable option after patients have undergone ovarian stimulation and oocyte retrieval. When the cancer treatment must be performed immediately, ovarian tissue or immature oocyte freezing is the best method for fertility preservation.

Today, ovarian tissue vitrification has been established with very promising results, which has been demonstrated as being comparable to slow freezing method. This technique seems very simple, and is also easier and cheaper to be offered to patients. Indonesia has started ovarian tissue and pre-antral follicles vitrification since 4 years ago with satisfying results. A pilot study was done on cervical and breast cancer patients as research model. Regarding ovarian tissue and isolated pre-antral follicles vitrification, the results were adequately satisfactory. Follicle morphology and in vitro culture is one of the methods used to assess the survival of warmed-vitrified follicles.

Today, trans-disciplinary collaboration is a really important factor in supporting the establishment of the Indonesian Fertility Preservation Center. A working group should at least consist of oncologists (gynecology, surgeon, pediatric, internal medicine), reproductive endocrinologists, counselors, nurses, and lawyers. Our challenge and opportunity is to set up a "one stop service" for young female cancer patients and survivors to have children, genetically from their own oocytes.

Are we ready to help our patients in saving hope for their future?

References